ImmunityBio Statistics
Share Statistics
ImmunityBio has 882.58M
shares outstanding. The number of shares has increased by 23.41%
in one year.
| Shares Outstanding | 882.58M |
| Shares Change (YoY) | 23.41% |
| Shares Change (QoQ) | 16.88% |
| Owned by Institutions (%) | 11.88% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 28,047 |
| FTD / Avg. Volume | 0.4% |
Short Selling Information
The latest short interest is 68.76M, so 7.79% of the outstanding
shares have been sold short.
| Short Interest | 68.76M |
| Short % of Shares Out | 7.79% |
| Short % of Float | 19.8% |
| Short Ratio (days to cover) | 14.52 |
Valuation Ratios
The PE ratio is -4.32 and the forward
PE ratio is -5.93.
ImmunityBio's PEG ratio is
0.09.
| PE Ratio | -4.32 |
| Forward PE | -5.93 |
| PS Ratio | 121.07 |
| Forward PS | 0.7 |
| PB Ratio | -3.66 |
| P/FCF Ratio | -4.48 |
| PEG Ratio | 0.09 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for ImmunityBio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.36,
with a Debt / Equity ratio of -1.03.
| Current Ratio | 3.36 |
| Quick Ratio | 3.21 |
| Debt / Equity | -1.03 |
| Debt / EBITDA | -2.09 |
| Debt / FCF | -1.27 |
| Interest Coverage | -2.23 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $21,683.82 |
| Profits Per Employee | $-608,182.35 |
| Employee Count | 680 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 2.12 |
Taxes
| Income Tax | 81K |
| Effective Tax Rate | -0.02% |
Stock Price Statistics
The stock price has increased by -74.38% in the
last 52 weeks. The beta is -0.1, so ImmunityBio's
price volatility has been lower than the market average.
| Beta | -0.1 |
| 52-Week Price Change | -74.38% |
| 50-Day Moving Average | 2.71 |
| 200-Day Moving Average | 3.58 |
| Relative Strength Index (RSI) | 36.78 |
| Average Volume (20 Days) | 7,062,895 |
Income Statement
In the last 12 months, ImmunityBio had revenue of 14.74M
and earned -413.56M
in profits. Earnings per share was -0.59.
| Revenue | 14.74M |
| Gross Profit | -2.81M |
| Operating Income | -344.18M |
| Net Income | -413.56M |
| EBITDA | -241.76M |
| EBIT | -281.99M |
| Earnings Per Share (EPS) | -0.59 |
Full Income StatementBalance Sheet
The company has 143.43M in cash and 504.17M in
debt, giving a net cash position of -360.74M.
| Cash & Cash Equivalents | 143.43M |
| Total Debt | 504.17M |
| Net Cash | -360.74M |
| Retained Earnings | -3.38B |
| Total Assets | 382.93M |
| Working Capital | 129.64M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -391.24M
and capital expenditures -6.89M, giving a free cash flow of -398.12M.
| Operating Cash Flow | -391.24M |
| Capital Expenditures | -6.89M |
| Free Cash Flow | -398.12M |
| FCF Per Share | -0.57 |
Full Cash Flow StatementMargins
Gross margin is -19.05%, with operating and profit margins of -2334.23% and -2804.77%.
| Gross Margin | -19.05% |
| Operating Margin | -2334.23% |
| Pretax Margin | -2804.77% |
| Profit Margin | -2804.77% |
| EBITDA Margin | -1639.63% |
| EBIT Margin | -2334.23% |
| FCF Margin | -2700.06% |
